Skip to main content

Table 3 Results

From: Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy

Site

 

SM CL

SM CL (non-sparing)

PG IL

PG IL (non-sparing)

PG CL

PG CL (non-sparing)

Sp C

Sp C (non-sparing)

V B ≥95%

V E ≥95%

A

mean

33.7

51.5

34.2

33.3

21.8

21.4

42.1

41.9

99.3

98.9

 

range

(46.5-57.3)

(24.7-41.6)

(16.6-54.3)

(16.3-53.2)

(12.2-31.8)

14.2-32.1)

(37-50)

(35.8-49)

(98.9-99.9)

(98.2-99.5)

B

mean

32.4

49

27.9

27.8

22

21.9

36.4

36.3

99.7

98.5

 

range

(44.3-52.8)

(29.7-39.5)

(16.4-55.5)

(16-55.7)

(16.7-30.6)

(16.7-30.3)

(23-49.8)

(23-49.8)

(99-99.9)

(97.9-98.9)

C

mean

35.1

47.1

28.7

29.1

21.9

22

40

39.8

98.5*

98.9

 

range

(43.7-52.4)

(26.6-40.6)

(16.5-48.2)

(17-46.3)

(13.6-30.9)

(14.5-30.7)

(30-44.9)

(29.7-45.3)

(96.2-99.6)

(97.9-98.9)

D

mean

33.4

46.4

21.2

21

16.2

16

36.4

36

99.6

98.3

 

range

(42.2-51.8)

(30-36.8)

(12.7-35.7)

(12.4-35.6)

(10.7-26.1)

(10.3-26.3)

(24.7-41)

(24.4-41.2)

(99.1-99.9)

(97.6-98.9)

  1. A: oropharynx, elective dose 57.75 Gy (14 patients) Doses in Gy
  2. B: larynx/hypopharynx, elective dose 57.75 Gy (7 patients) Sp C: spinal cord
  3. C: oropharynx, elective dose 54.25 Gy (6 patients)
  4. D: larynx/hypopharynx, elective dose 54.25 Gy (4 patients)
  5. V B ≥95%:% of PTV boost receiving ≥95% of the prescribed dose
  6. V E ≥95%:% of PTV elective receiving ≥95% of the prescribed dose
  7. *: in 1 patient with T1 carcinoma of the soft palate, 96.2% of PTVboost received 95% of prescribed dose, this was accepted because of the fact that a large part of the PTVboost consisted of air.